Aleksandrya de la Cruz
Nurse Practitioner · Temecula, CANPI 1336625524
Payments from drug & device makers
Across 605 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Teva Pharmaceuticals USA, Inc.$4K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Biogen$772
- Novartis$765
- Abbott$346
- plus $2K from 29 others
What the payments were for
- Consulting fees$8004%
- Speaking & faculty fees$6,31332%
- Travel & lodging$1,1546%
- Food & beverage$10,91656%
- Education$4592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 156 | $9,459 |
| Teva Pharmaceuticals USA, Inc. | 176 | $3,929 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $2,180 |
| Biogen | 52 | $772 |
| Novartis | 104 | $765 |
| Abbott | 4 | $346 |
| Neurocrine Biosciences, Inc. | 9 | $237 |
| Lundbeck LLC | 7 | $190 |
| Lilly USA, LLC | 9 | $187 |
| UCB, Inc. | 7 | $175 |
| Biohaven Pharmaceuticals, Inc. | 13 | $172 |
| Medtronic | 1 | $155 |
| Pfizer | 8 | $149 |
| Octapharma USA, Inc. | 7 | $148 |
| Neurelis, Inc. | 3 | $89 |
| EMD Serono, Inc. | 4 | $79 |
| Acadia Pharmaceuticals Inc | 3 | $70 |
| Avanir Pharmaceuticals, Inc. | 3 | $69 |
| SK Life Science, Inc. | 3 | $61 |
| Amgen | 2 | $55 |
| Grifols USA, LLC | 3 | $55 |
| Johnson & Johnson | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Adamas Pharmaceuticals, Inc. | 1 | $25 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| AstraZeneca | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Banner Life Sciences, LLC | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Avion Pharmaceuticals | 1 | $16 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$4,062
- UBRELVY$3,250
- NURTEC ODT$1,953
- INFINITY$196
- SYMPLICITY G3$155
- TYSABRI$125
How this compares
$19,642 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 37 | $200,106 |
| Nurtec OdtRimegepant Sulfate | 58 | $71,215 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 43 | $32,714 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $29,986 |
| QuliptaAtogepant | 28 | $26,784 |
| Emgality PenGalcanezumab-Gnlm | 23 | $17,888 |
| UbrelvyUbrogepant | 11 | $11,132 |
| Lacosamide | 14 | $3,932 |
| Memantine Hcl | 74 | $3,315 |
| Dimethyl Fumarate | 12 | $2,674 |
| Donepezil Hcl | 68 | $2,290 |
| Duloxetine Hcl | 24 | $1,660 |
| Quetiapine Fumarate | 75 | $1,487 |
| Risperidone | 30 | $1,223 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 32 | $1,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $70 | $200,10637 claims |
| PfizerNurtec Odt | $149 | $71,21558 claims |
| AbbVieQulipta, Ubrelvy | $9,459 | $37,91639 claims |
| Lilly USA, LLCOlanzapine | $187 | $66418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Temecula
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.